Contineum Therapeutics (CTNM) Research & Development (2023 - 2026)
Contineum Therapeutics (CTNM) posted quarterly Research & Development of $12.7 million for Q2 2026, down 9.68% year-over-year from $14.1 million in Q2 2025, and up 9.05% quarter-over-quarter from $11.6 million in Q1 2026.
Contineum Therapeutics (CTNM) Research & Development (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $12.7 million for Q2 2026.
- In Q2 2026, Research & Development fell 9.68% year-over-year to $12.7 million; the TTM figure through Jun 2026 stood at $48.1 million (down 4.79% YoY), while the FY2025 annual figure was $51.5 million, up 34.1% from the prior year.
- Research & Development for Q2 2026 stood at $12.7 million, up from $11.6 million in the prior quarter.
- The five-year high for Research & Development was $14.1 million in Q2 2025, with the low at $3.6 million in Q1 2023.
- The 4-year median for Research & Development is $10.4 million (2024), against an average of $10.1 million.
- Peak annual rise in Research & Development reached 114.15% in 2024, while the deepest fall reached 16.48% in 2024.
- Contineum Therapeutics' Research & Development stood at $8.0 million in 2023, then surged by 62.44% to $13.0 million in 2024, then declined by 2.0% to $12.8 million in 2025, then slipped by 0.42% to $12.7 million in 2026.
- Business Quant data shows CTNM's Research & Development at $12.7 million in Q2 2026, $11.6 million in Q1 2026, and $12.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Contineum Therapeutics | 533.73 Mn | 533.73 Mn | - | 12.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.70 Mn |
| Mar 31, 2026 | 11.65 Mn |
| Dec 31, 2025 | 12.76 Mn |
| Sep 30, 2025 | 10.99 Mn |
| Jun 30, 2025 | 14.06 Mn |
| Mar 31, 2025 | 13.71 Mn |
| Dec 31, 2024 | 13.02 Mn |
| Sep 30, 2024 | 9.73 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 7.78 Mn |
| Dec 31, 2023 | 8.01 Mn |
| Sep 30, 2023 | 6.50 Mn |
| Jun 30, 2023 | 9.46 Mn |
| Mar 31, 2023 | 3.63 Mn |